Applications for clinical trials of Beda Pharmaceuticals' innovative bpi-27336 drug were accepted

February 19, Beda Pharmaceuticals announced that the company's declared BPI-28592 drug clinical trial application has been accepted by the State Drug Administration for the treatment of solid tumor patients.According to the announcement, BPI-28592 is a new molecular solid compound developed by Beda Pharmaceuticals with fully independent intellectual property rights, and is a new type of powerful, highly selective primary myoprotein receptor kinase (Tropomyosin receptorkinase, abbreviated as T RK, also known as neurotrophic receptor tyrosine kinase, abbreviated as NTRK) second-generation oral small molecule inhibitors, can cover a variety of cancer species and is intended for the treatment of patients with locally advanced or metastatic solid tumors with NTRK gene variants.Currently, only two TRK inhibitors are commercially available, with Larotrectinib (developed jointly by Bayer and Loxo Oncology) listed in the United States, Entrectinib (developed by Roche Group member Ignyta) listed in the United States and Japan, TRK inhibitors not yet available in China, and the medical needs of patients with TRK variant cancer are far from being met.BPI-28592 belongs to the second generation of TRK inhibitors, preclinical data show that its biological activity in animals is consistent, can effectively inhibit tumor cell proliferation, and can be effective in Lalotrectinib drug-resistant mutations such as TRKA G595R, TRKC G623, it is expected to provide a new molecularly targeted treatment for NTRK mutation tumor patients to provide more benefits.BPI-28592 belongs to the category 1 of chemicals registered as "innovative drugs that are not listed at the domestic or foreign level".
(Sina Pharmaceutical News)